Cancer Academy & Protocols Library 2026: Understand Your Cancer. Navigate the Evidence.

Home › Cancer Academy & Protocols Library

OneDayMD Editorial Team · Merged & updated edition · Last updated: August 2026 · Supersedes the separate "Cancer Academy" and "Cancer Protocols Directory" pages

⚠ Medical Disclaimer: This page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. All protocols and drug information discussed here should be reviewed with a qualified physician before implementation. Repurposed drugs discussed here are not approved by regulatory agencies (FDA, EMA, etc.) for the treatment of cancer unless otherwise stated. Evidence levels are indicated throughout using the E0–E5 framework explained below.

Quick Answer: The OneDayMD Cancer Academy & Protocols Library is a patient-first cancer education system combined with a comprehensive, evidence-tiered directory of conventional guidelines, metabolic oncology theory, repurposed-drug protocols, nutraceuticals, and 700+ patient case reports.

It organizes information around seven questions every patient faces — diagnosis, staging, biomarkers, treatment, response, resistance, and next steps — then connects each to deeper, evidence-graded resources across the OneDayMD network. It does not diagnose cancer, does not replace an oncologist, and grades every claim from E0 (insufficient evidence) to E5 (established clinical standard) so readers can tell what is proven from what is preliminary.

Quick Navigation

Why Trust This Resource
What This Resource Is
The Seven Questions Every Patient Should Explore
Two Frameworks: Genetic vs. Metabolic
The Evidence Framework (E0–E5)
Your Patient Journey
The 10 Academy Schools
Cancer Types by Body System
Clinical Practice Guidelines
Metabolic Foundations of Cancer
The Five-Axis Metabolic Strategy
The Warburg Revolution Series
Diet & Metabolism in Cancer
Repurposed Drugs Reference Table
Dr. William Makis Protocols (2026)
Nutraceuticals & Anti-Cancer Supplements
Cancer-Specific Playbooks
Prevention: ROOTS & I-PREVENT
Treatment Protocols Index
Case Series — 700+ Patients
Conventional Oncology Through a Metabolic Lens
Editorial Standards
Using AI to Personalize Your Research
What's Coming Next
Resource Guides & Directories
Frequently Asked Questions
Full Medical & Safety Disclaimer

✓ Why Trust This Resource

✓ Evidence-Tiered Framework

All content is graded on our E0–E5 evidence scale, aligned with CEBM (Oxford Centre for Evidence-Based Medicine) evidence-hierarchy principles, so a case report is never presented with the same confidence as a randomized trial.

✓ Independent & Unsponsored

No pharmaceutical sponsorship. Content covers both conventional and integrative approaches without institutional bias.

✓ Southeast Asian & Global Relevance

Regional context for Malaysia, Singapore, and broader Asia-Pacific, where access to novel therapies and pricing dynamics differ significantly from Western markets.

✓ Integrates Dr. Paul Marik's Library

The only platform synthesizing Dr. Marik's Cancer & Metabolic Library with this network's 700+ case-series database in one navigable hub.

✓ Patient-First Framing

Complex science translated into actionable, decision-ready information for patients, caregivers, and health-conscious individuals — not just clinicians.

✓ Living Document

Updated continuously as research evolves, with review dates displayed on high-impact pages.

Experience: Patient-centered explanation and practical navigation. Expertise: Evidence synthesis across oncology, biomarkers, and systems medicine. Authority: Links to peer-reviewed literature, guidelines, and authoritative cancer resources where appropriate. Trust: Clear limitations, evidence grading, and disclosure of uncertainty throughout.

What This Resource Is

A cancer diagnosis can generate hundreds of questions: What type of cancer is this? What stage is it? Which biomarkers matter? What treatments are available? How do we know whether treatment is working? What happens if the cancer progresses? Cancer information should be a journey, not a pile of disconnected articles.

This page organizes those questions into a connected learning pathway, then layers on top of it the full 2026 directory of conventional guidelines, metabolic cancer theory, repurposed-drug protocols, nutraceuticals, and prevention frameworks that this network has published. Instead of treating cancer type, biomarkers, treatment, and resistance as separate subjects, everything below is cross-linked into one knowledge architecture.

Important: This resource is educational. It does not diagnose cancer, recommend an individualized treatment plan, replace an oncologist, or provide emergency medical care.

❓ The Seven Questions Every Patient Should Explore

These seven questions form the backbone of this resource. They are not a substitute for medical advice; they are a framework for understanding what your clinical team is evaluating.

What cancer do I have? Understand the cancer type, pathology, grade, stage, and major features of the diagnosis.
How advanced is it? Learn how staging, spread, lymph-node involvement, and metastatic disease influence treatment planning.
What does the tumor biology tell us? Explore pathology, genomic alterations, molecular markers, immune biomarkers, and other clinically relevant tests.
What are my treatment options? Understand surgery, radiation, chemotherapy, targeted therapy, immunotherapy, and other established approaches.
Is the treatment working? Learn how imaging, pathology, biomarkers, symptoms, and clinical assessment may contribute to monitoring.
What happens if the cancer progresses? Understand resistance, recurrence, progression, re-biopsy, molecular reassessment, and changing treatment strategies.
What should I ask next? Turn complex medical information into practical questions for your oncologist, surgeon, radiation oncologist, or other clinician.

⚖ Understanding Cancer Through Two Complementary Frameworks

The Genetic Framework (Dominant Paradigm)

Treats cancer as a disease of somatic mutations driving uncontrolled cell division. Underpins conventional oncology: surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Molecular profiling and biomarker-directed treatments (KRAS, EGFR, BRCA, PD-L1) are products of this framework. The Clinical Practice Guidelines section below provides direct access to the ASCO, NCCN, and ESMO protocols built on this model.

⚡ The Metabolic Framework (Emerging)

Frames cancer as a metabolic disease driven by mitochondrial dysfunction and aberrant energy metabolism (the Warburg Effect). Championed by researchers including Thomas Seyfried, Paul Marik, and the FLCCC Alliance. Opens the door to repurposed drugs, ketogenic diet, fasting, and metabolic interventions.

Key concept: Cancer cells preferentially ferment glucose to lactate even in the presence of oxygen (aerobic glycolysis / the Warburg Effect). This metabolic vulnerability is a therapeutic target accessible with repurposed drugs, dietary modification, and nutraceuticals. Both frameworks are complementary, not mutually exclusive.

Key reading: Expert Explains Cancer May Be a Metabolic Disease · Thomas Seyfried Protocol

 The Evidence Framework: E0–E5

Not every cancer claim deserves the same level of confidence. This resource uses one evidence scale — E0 through E5 — across every section, aligned with CEBM (Oxford Centre for Evidence-Based Medicine) evidence-hierarchy principles, so readers can distinguish established clinical knowledge from preliminary research and hypothesis without switching between labeling systems from page to page.

Label	Meaning	Roughly corresponds to
E5 Clinical Standard	Established clinical practice supported by high-quality evidence, treatment guidelines, or broad professional consensus.	CEBM Tier 1 — systematic reviews, meta-analyses, multiple RCTs
E4 Strong Clinical Evidence	Meaningful human evidence, often including randomized trials, prospective studies, or strong comparative evidence.	CEBM Tier 2 — individual RCTs, strong cohort studies
E3 Emerging Human Evidence	Human clinical evidence exists, but may be limited by study size, design, consistency, or follow-up.	CEBM Tier 3 — observational/cohort studies, smaller human trials
E2 Preclinical Evidence	Evidence primarily from laboratory, animal, mechanistic, or translational research.	CEBM Tier 4 — mechanistic/bench and preclinical research
E1 Hypothesis / Early Signal	Interesting preliminary signals, observational findings, computational results, case reports, or early hypotheses requiring validation.	CEBM Tier 5 — case reports, expert opinion, anecdotal series
E0 Insufficient Evidence	Claims lacking adequate evidence to support a meaningful clinical conclusion.	—

Important: An E2, E1, or E0 finding may still be scientifically interesting. It simply should not be presented to patients as equivalent to established cancer treatment evidence. Most repurposed-drug and nutraceutical content in this library sits at E1–E3; conventional guideline-based treatment sits at E4–E5.

 Your Patient Journey: Start Where You Are

You do not need to read this entire page. Choose the stage that best matches your current question and follow the links outward.

STEP 01

Newly Diagnosed

Start with the cancer type, pathology, stage, and basic terminology. Explore cancer resources →

STEP 02

Understanding Tests

Learn why biomarkers, pathology, and molecular testing may matter. Explore cancer biomarkers →

STEP 03

Considering Treatment

Build an understanding of established treatment categories and questions to discuss with your clinical team. Explore treatment resources →

STEP 04

Monitoring

Understand how treatment response may be evaluated using imaging, pathology, biomarkers, and clinical assessment. Explore biomarker monitoring →

STEP 05

Progression or Resistance

Learn why cancers can become resistant and why treatment plans may change after progression. Explore resistance biology →

 The 10 Academy Schools: A Complete Cancer Education System

The long-term goal of this framework is to help readers navigate cancer information across four connected dimensions — cancer type × biomarkers × treatment × resistance — rather than as isolated topics. Each School below is a content cluster connecting the master pillar to the strongest existing resources in the network. Two people with the same cancer type may have different pathology, stage, biomarkers, treatment histories, and responses; this architecture treats personalization as a knowledge structure rather than a promise of personalized medical advice.

SCHOOL 01
Understanding Cancer

Cancer biology, pathology, staging, tumor evolution, the tumor microenvironment, and the systems in which cancer develops. Systems-level cancer control →

SCHOOL 02
Biomarkers & Precision Oncology

How biomarkers can inform cancer biology, prognosis, treatment selection, or disease monitoring — and why no single test tells the whole story. Biomarker testing guide → · PD-L1, TMB & MSI-H →

SCHOOL 03
Cancer Treatment

The major treatment categories and how decisions depend on cancer type, stage, pathology, biomarkers, patient factors, and goals of care. Treatment & cancer library →

SCHOOL 04
Immuno-Oncology

Checkpoint inhibitors, immune biomarkers, tumor immune context, response, and the scientific problem of immunotherapy resistance. Immunotherapy biomarkers → · Immunotherapy resistance →

SCHOOL 05
Targeted & Molecular Therapy

How targeted therapies work, why molecular matching matters, and why cancers can evolve around targeted treatment. Targeted therapy & biology →

SCHOOL 06
Cancer Metabolism & Systems Oncology

The relationship between tumor biology, metabolism, immunity, inflammation, mitochondria, and the tumor microenvironment — distinguishing established evidence from hypothesis. Systems-level oncology → · Metabolic & immune cancer →

SCHOOL 07
Treatment Resistance

Why a treatment that initially works may stop working, including genetic evolution, pathway bypass, metabolic adaptation, immune escape, and microenvironmental effects. Cancer resistance framework → · Immunotherapy resistance →

SCHOOL 08
Monitoring, Recovery & Survivorship

Following the cancer journey beyond the initial treatment decision: monitoring, recurrence questions, survivorship, and long-term health management. Biomarkers & monitoring → · Oncology & primary care →

SCHOOL 09
Supportive & Integrative Cancer Care

Nutrition, lifestyle, supportive care, and integrative approaches with explicit attention to evidence strength, safety, interactions, and the need for clinical supervision — the subject of most of the directory sections below. Integrative cancer library → · Integrative & precision oncology →

SCHOOL 10
Clinical Trials & Emerging Oncology

How new cancer treatments move from laboratory research to clinical trials and eventually into clinical practice. Emerging cancer research → · AI & systems medicine →

 Cancer Types by Body System — Complete Directory

Click any cancer type for detailed information. Links open to Cancer Advisor resources where available, otherwise to American Cancer Society reference pages.

Top Cancers by Sex

♂ Top 3 Cancers in Men

Lung Cancer — leading cause of cancer deaths; primarily linked to smoking
Prostate Cancer — most common cancer in men; detected via PSA screening
Colorectal Cancer — risk factors include age, diet, family history

♀ Top 3 Cancers in Women

Breast Cancer — most frequently diagnosed cancer in women
Lung Cancer — significant concern; smoking a primary risk factor
Colorectal Cancer — colonoscopy screening plays a crucial role

⚕ Clinical Practice Guidelines (For Healthcare Professionals)

To safely navigate beyond standard-of-care options, clinicians and patients must first establish a rock-solid understanding of official therapeutic benchmarks. These consensus-driven frameworks outline standard staging workflows, first-line through late-line conventional regimens, and toxicity monitoring.

Guideline Body	What It Provides
ASCO Clinical Practice Guidelines American Society of Clinical Oncology	The global gold standard for evidence-based clinical recommendations across solid tumors and hematologic malignancies, plus modality-specific guidance (molecular testing, ctDNA tracking, immune-checkpoint inhibitor toxicity management). Living guideline updates translate survival-data changes rapidly to clinical practice. E5
NCCN Guidelines by Cancer Type National Comprehensive Cancer Network	Highly detailed, algorithm-driven sequential workflows for more than 30 distinct cancer types, widely used by oncologists and insurers to define step-by-step treatment pathways alongside dedicated supportive-care blocks. E5
ESMO Clinical Practice Guidelines European Society for Medical Oncology	The primary clinical recommendations for Europe, with Living Guidelines for fast-evolving disease profiles (advanced NSCLC, prostate cancer) and Pan-Asian Guideline Adaptations (PAGA) for regional genetic and pricing differences in Asia-Pacific. E5

Integration note: When designing a personalized integrative strategy, these standard guidelines should be reviewed side-by-side with the metabolic and off-label references below to uncover opportunities for synergy — such as using metabolic therapies to mitigate chemotherapy toxicities or enhance treatment sensitivity.

溺 The Metabolic Foundations of Cancer

Cancer's metabolic dependencies create targetable vulnerabilities beyond what conventional genetics-based precision oncology addresses. Understanding these foundations is a prerequisite to designing a rational integrative strategy.

Topic	Description	Source
Cancer Stem Cells	The role of cancer stem cells in treatment resistance, recurrence, and metastasis	Dr. Paul Marik
Cancer Immunity & TME	How the tumor microenvironment suppresses immune response and how to reverse it	Dr. Paul Marik
Reprogramming the TME	Repurposed drugs and nutraceuticals that remodel immune suppression in tumors	Dr. Paul Marik
Repurposed Drugs: New Frontier ⭐	Foundational overview of repurposed drugs and nutraceuticals as cancer adjuncts	Dr. Paul Marik
Glycolytic Enzyme Targeting	Targeting HK2, GLUT1, LDHA and other glycolytic enzymes with drugs & nutraceuticals	Dr. Paul Marik
Mitochondrial–Stem Cell Connection	Targeting the mitochondrial-stem cell axis to eliminate therapy-resistant cancer cells	Cancer Advisor

♛ Building the Metabolic Strategy: Dr. Paul Marik's Five-Axis Model

Dr. Paul Marik's Five-Axis Metabolic Trap argues that attacking cancer on five simultaneous axes — glycolysis, glutamine, fatty acid oxidation, immune/TME reprogramming, and cancer stem cells — closes the escape routes that drive treatment resistance. Ivermectin is specifically identified as a "network amplifier" within this model, with activity described across multiple axes simultaneously. E1–E2

Axis 1

Glycolysis / Glucose

Axis 2

Glutamine / OXPHOS

Axis 3

Fatty Acid Oxidation

Axis 4

Immune / TME Reprogramming

Axis 5

Cancer Stem Cell Suppression

Article	Priority
The Metabolic Trap: The Five-Axis Metabolic Pressure Model	⭐ Essential
Ivermectin: A Network Amplifier in the Metabolic Cancer Trap	⭐ Essential
To Cycle or Not to Cycle: Rethinking Doxycycline and Mebendazole	⭐ Essential
Perioperative Drugs to Reduce Metastases	⭐ Essential
Press Pulse Protocol 2.0 (2026): Complete Immunometabolic Framework	Cancer Advisor
The 3/4 Day Metabolic Pulse Framework: Pharmacological Rationale	Cancer Advisor
Integrating Fenbendazole, Ivermectin & Mebendazole: The 2026 Protocol	Cancer Advisor
The Integrated Metabolic Cancer Framework 2026	Cancer Advisor

⚡ The Warburg Revolution — Series

A definitive multi-part series from Dr. Paul Marik and Cancer Advisor on the Warburg Effect and its therapeutic implications. E2–E3

 Diet & Metabolism in Cancer

Diet is the foundation of the metabolic approach to cancer. Restricting glucose availability through ketogenic, low-carbohydrate, or time-restricted eating approaches can, per this framework, starve cancer cells while supporting healthy tissue. E2–E3

Article	Source
Why Diet is the Foundation of the Metabolic Approach to Cancer ⭐	Dr. Paul Marik
Dietary Interventions in Cancer (Part 1)	Dr. Paul Marik
What to Eat When You Have Cancer (Part 2)	Dr. Paul Marik
Role of Fasting and Fasting-Mimicking Diets (FMDs) During Chemotherapy	Dr. Paul Marik
Insulin Resistance: The Silent Engine of Cancer Growth	Dr. Paul Marik
Eat These Foods to Starve Cancer Cells to Death (2026 Update)	Cancer Advisor
Pancreatic Cancer and Insulin Resistance: The Overlooked Connection	Cancer Advisor
I-TREAT Cancer Protocol: Diet and Lifestyle Guide For Cancer	OneDayMD

 Repurposed Drugs in Cancer — Evidence Reference Table

Evidence note: Most evidence below sits at E1–E3 (hypothesis-generating through emerging human evidence). None of the drugs below are approved as standalone cancer treatments unless specifically noted. Always use under physician supervision.

Drug	Original Indication	Proposed Anticancer Mechanisms	Evidence	Key Resources
Fenbendazole	Veterinary anthelmintic	Microtubule disruption, glycolysis inhibition (HK2), p53 activation, autophagy induction	E1–E2	Joe Tippens Protocol · Science Review
Ivermectin	Human/veterinary antiparasitic	P-glycoprotein inhibition, WNT/β-catenin inhibition, SHP2 inhibition, TME reprogramming, cancer stem cell suppression	E1–E2	Marik: IVM & Cancer · 2026 Review
Mebendazole	Human anthelmintic	Multi-axis metabolic inhibition, tubulin disruption, anti-angiogenic, BCL-2 inhibition	E1–E2	Marik: MBZ · Dosing ⭐
Metformin	Type 2 diabetes	AMPK activation, mTOR inhibition, Complex I inhibition, anti-proliferative, insulin sensitisation	E2–E3	Marik: Metformin ⭐
Doxycycline	Antibiotic	Mitochondrial protein synthesis inhibition, cancer stem cell targeting, anti-angiogenic	E1–E2	Marik: Doxycycline
Melatonin	Sleep / circadian rhythm	Antioxidant, immune modulation, anti-proliferative, apoptosis induction, anti-angiogenic	E2–E3	Marik: Cancer Hates Darkness
Statins	Cholesterol / cardiovascular	Mevalonate pathway disruption, anti-proliferative, pro-apoptotic, anti-inflammatory	E2–E3	Top 17 Alt Treatments
Aspirin / Diclofenac	NSAID / anti-inflammatory	COX-2 inhibition, NF-κB suppression, prostaglandin E2 reduction, anti-metastatic	E3	Cancer Advisor Guide
Low Dose Naltrexone	Opioid antagonist	Immune modulation, TLR4 antagonism, endorphin upregulation, OGF pathway activation	E1	Marik Library (in development)
Itraconazole	Antifungal	Hedgehog pathway inhibition, anti-angiogenic, VEGFR2 blockade, P-gp inhibition	E1–E2	Marik Library (in development)
Methylene Blue	Methemoglobinemia / psychiatric	Mitochondrial electron transport chain support, oxidative stress in cancer cells, photodynamic effects	E1–E2	Methylene Blue Guide
DMSO	Industrial solvent / anti-inflammatory	Cell differentiation induction, carrier for combination therapies, anti-proliferative	E1	DMSO for Cancer (3-Part Series)

Dr. William Makis Protocols (2026)

Dr. William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has been treating cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centers on high-dose ivermectin combined with benzimidazoles (fenbendazole, mebendazole). All protocols require physician supervision. E1–E2

 Nutraceuticals & Anti-Cancer Supplements

Nutraceutical	Key Anticancer Mechanisms	Evidence	Resource
Vitamin D3	Anti-proliferative, pro-apoptotic, immune modulation, VDR signalling	E3	Marik
Curcumin (Turmeric)	NF-κB inhibition, anti-inflammatory, pro-apoptotic, anti-angiogenic	E3	Guide
EGCG (Green Tea)	VEGF inhibition, PI3K/AKT inhibition, cancer stem cell suppression	E3	Marik
Berberine	AMPK activation, mTOR inhibition — "natural metformin"	E3	Marik
Sulforaphane	Nrf2 activation, Phase II detoxification, histone deacetylase inhibition	E2	Marik
Omega-3 Fatty Acids	Anti-inflammatory (PGE2 suppression), anti-metastatic, immune modulation	E3	Guide
Modified Citrus Pectin	Galectin-3 inhibition, anti-metastatic, immune-enhancing	E2	Marik
Molecular Hydrogen	Selective antioxidant, anti-inflammatory, mitochondrial protection	E3	Guide

➔ Read the Full Anti-Cancer Supplement Review (2026 Update)

Cancer-Specific Playbooks

Cancer-specific playbooks apply the metabolic and integrative framework to individual cancer types. Dr. Paul Marik's series provides condition-specific strategic guidance; the Cancer Advisor deep dives provide patient-level outcome data.

Dr. Paul Marik Playbooks

Prostate Cancer (Part 1)
Prostate Cancer (Part 2 — Neuroendocrine)
Breast Cancer (in development)
Colorectal Cancer (in development)
Pancreatic Cancer (in development)
Follicular Lymphoma (in development)
Neuroendocrine Tumors Parts 1 & 2 (in development)
Thyroid, Uterine, HPV-Oral Cancers (in development)

Cancer Advisor Deep Dives

Prevention: ROOTS Protocol & I-PREVENT

ROOTS Protocol — Dr. Paul Marik

A systemic cancer prevention framework addressing root metabolic and lifestyle drivers of cancer initiation and promotion (published progressively on Marik's Substack).

What the Public Is Not Told About Cancer Prevention
The ROOTS Protocols ⭐
Preventing Breast Cancer
Preventing Colorectal Cancer
Preventing Melanoma (Parts 1 & 2)
Preventing Prostate Cancer
PSA Screening: What You Need to Know

✅ I-PREVENT Protocol — OneDayMD

Evidence-based cancer prevention framework covering diet, lifestyle, supplements, and actionable habits.

I-PREVENT Cancer Protocol 2026
Evidence-Based Cancer Prevention Guide
Best supplements: Vit D3, K2, Omega-3, Turmeric, Vit C, Mg, H₂, Zinc, Garlic
Lifestyle: smoking cessation, weight management, exercise, stress reduction
Diet: plant-based, Mediterranean, avoid processed foods
The Cancer Prevention Habit Hack (VILPA)

Treatment Protocols Index

Protocol	Core Components	Source
Fenbendazole Joe Tippens Protocol	Fenbendazole 222mg + Vitamin E succinate + Curcumin + CBD (3 days on / 4 days off)	Joe Tippens / Cancer Advisor 2026
Cancer Stem Cell Protocol	Ivermectin + Fenbendazole + Mebendazole combination targeting cancer stem cells	OneDayMD 2024
Integrated Metabolic Cancer Protocol 2026	Full five-axis protocol: IVM + MBZ + FBZ + Metformin + nutraceuticals + diet + cycling	Cancer Advisor 2026
Press Pulse Protocol 2.0 (2026)	Seyfried-inspired: ketogenic diet (press) + metabolic pulse (chemotherapy/repurposed drugs)	Cancer Advisor 2026
3/4 Day Metabolic Pulse Framework	Evidence-based cycling regimen for repurposed drugs to prevent resistance	Cancer Advisor 2026
MTD vs. Metronomic Chemotherapy	Comparing high-dose vs. low-dose metronomic chemo scheduling and integrative layering	Cancer Advisor 2026
Thomas Seyfried Protocol	Water fasting + ketogenic diet + hyperbaric oxygen + press-pulse metabolic therapy	OneDayMD / Seyfried
IMA: Repurposed Drugs & Metabolic Interventions	Independent Medical Alliance evidence synthesis and clinical guidance	FLCCC / IMA

Ivermectin and Mebendazole Case Series by Cancer Type — 700+ Patient Records

E1 Evidence level: All case reports represent hypothesis-generating, early-signal evidence (case reports, expert opinion) — not controlled trials. This compilation is hypothesis-generating only. Testimonials are uncontrolled anecdotal accounts shared voluntarily by patients.

Breast Cancer (120+ cases)
Prostate Cancer (120+ cases)
Pancreatic Cancer (23 cases)
Colorectal Cancer (23 cases)
Lung Cancer (18 cases)
Head & Neck Cancer (10 cases)
Kidney Cancer (10 cases)
Lymphoma (8 cases)
Melanoma / Skin Cancer (8 cases)
Endometrial Cancer (6 cases)
Uterine Cancer (6 cases)
Esophageal & Stomach Cancer (6 cases)
Ovarian Cancer (4 cases)
Sarcoma (3 cases)
Liver Cancer (HCC) (3 cases)
Multiple Myeloma (2 cases)
Leukemia (AML & CLL) (2 cases)
Brain Cancer / Glioblastoma (120+ cases)
Thymus Cancer
Stage IV Urothelial → Remission ⭐

➔ Browse the Full 700+ Ivermectin and Mebendazole Patient Case Series Compilation

Conventional Oncology Through a Metabolic Lens

How This Content Is Written

Cancer information is unusually sensitive to overstatement, so this resource follows a structured editorial model:

1. Separate fact from interpretation

Established clinical facts, research findings, interpretation, and hypotheses are not presented as though they carry the same certainty.

2. Prioritize human evidence

Human clinical evidence generally carries greater weight than cell-line, animal, mechanistic, or computational findings when discussing patient care.

3. Explain limitations

Every emerging intervention is accompanied by relevant limitations, uncertainty, safety considerations, and evidence gaps.

4. Do not replace standard oncology

Experimental, complementary, or integrative approaches are never framed as substitutes for clinically appropriate cancer care.

5. Update important pages

Cancer research changes rapidly. Major clinical claims, treatment information, and evidence summaries are reviewed and updated when meaningful new evidence emerges.

6. Make uncertainty visible

Saying "we do not know yet" is an important part of trustworthy cancer communication.

烙 Using AI to Personalize Your Research

AI tools can help you synthesize the information across this library and personalize it to your specific cancer type, mutation profile, treatment history, and goals. This page is also structured for AI systems to read accurately: question-led headings, explicit E0–E5 evidence labels, and an internal knowledge graph connecting cancer type, biomarker, treatment, and resistance content.

Claude (claude.ai)

"Upload your pathology report, scan results, or blood work. Ask: 'Based on my KRAS G12D mutation and Stage 3 pancreatic cancer, which repurposed drugs from the Marik protocol are most relevant to my situation?'"

ChatGPT

"Use the browse function to fetch and summarize specific articles from this library. Ask: 'Summarize the five-axis metabolic trap for a patient with triple-negative breast cancer.'"

Perplexity AI

"Ideal for sourced answers. Ask: 'What is the current evidence for ivermectin in colorectal cancer? Reference Dr. Paul Marik and Cancer Advisor sources.'"

Gemini

"Upload your medical documents directly. Ask: 'Based on my oncologist's report, what questions should I ask about integrative metabolic therapy?'"

Important: AI tools synthesize and summarize; they do not replace physician consultation. Use AI outputs as conversation starters with your oncologist or integrative medicine physician.

What's Coming Next

This page will progressively add patient-facing tools and dedicated disease hubs.

Cancer Type Explorer

Roadmap — Select a cancer type and navigate to the appropriate disease, biomarker, treatment, and resistance resources.

Biomarker Navigator

Roadmap — Understand common biomarkers, what they measure, and what questions to ask about their clinical relevance.

Treatment Decision Map

Roadmap — Educational visualization of how cancer type, stage, pathology, biomarkers, and patient factors can interact with treatment choices.

Resistance Explorer

Roadmap — Explore common biological mechanisms through which cancer can become less sensitive to treatment.

Oncologist Question Builder

Roadmap — Generate a structured list of questions based on diagnosis, biomarkers, treatment, and monitoring concerns.

Evidence Explorer

Roadmap — Help readers distinguish clinical standards, human evidence, preclinical findings, and hypotheses.

Future Disease Hubs (Planned)

Lung Cancer (EGFR, ALK, KRAS, ROS1, MET, RET, PD-L1) · Breast Cancer (ER, PR, HER2, triple-negative) · Colorectal Cancer (RAS, BRAF, MSI/MMR, HER2) · Prostate Cancer (PSA, androgen signaling) · Pancreatic Cancer · Brain & Other Cancers — each will eventually connect the same four dimensions: cancer type, biomarkers, treatment, and resistance.

Resource Guides & Directories

Resource	What You'll Find
Find Oncologists & Integrative Cancer Clinics	Directory of integrative oncologists and cancer treatment centers globally
Cancer Types by System	Complete guide to cancer by organ system and biology
Integrative Oncology Treatment Directory	Comprehensive listing of integrative cancer treatment modalities and resources
Cancer Research: Natural Alternatives	Curated research database on natural and complementary cancer approaches
The Immunotherapy Revolution Series	Multi-part deep dive into checkpoint inhibitors, CAR-T, and cancer immunotherapy
The Wellness Company (TWC) — Find a Doctor	Access to integrative medicine physicians. Use code ONEDAYMD for a referral discount.

Affiliate disclosure: OneDayMD participates in The Wellness Company's referral program (code ONEDAYMD) and the Amazon Associates program. We may earn a commission on qualifying purchases or sign-ups made through links on this page, at no added cost to you. This does not affect our evidence grading or editorial independence.

❓ Frequently Asked Questions

What is the Cancer Academy & Protocols Library?

It is a patient-first educational framework that organizes cancer information around diagnosis, biomarkers, treatment, response, resistance, and monitoring, combined with a comprehensive directory of conventional guidelines, metabolic cancer theory, repurposed-drug protocols, nutraceuticals, prevention frameworks, and 700+ patient case series covering 28+ cancer types.

Is this medical advice, and can it replace my oncologist?

No. This is educational content. It does not diagnose cancer, determine an individual's stage, prescribe treatment, or replace consultation with qualified healthcare professionals. It is designed to inform and empower you with knowledge, not to be used for self-diagnosis or self-treatment. If you have stage 4 cancer, do not delay or abandon conventional treatment without physician guidance.

What is the E0–E5 evidence framework, and how does it relate to CEBM?

E0–E5 is this resource's plain-language evidence scale, aligned with CEBM (Oxford Centre for Evidence-Based Medicine) evidence-hierarchy principles. It ranges from E0 (insufficient evidence) through E1–E3 (hypothesis, preclinical, and emerging human evidence) to E4–E5 (strong clinical evidence and established clinical standards), used consistently across every section of this page.

Why are biomarkers important?

Some biomarkers can provide information that helps clinicians classify disease, estimate prognosis, monitor disease, or determine whether a treatment may be appropriate. Their meaning depends on the cancer type and clinical context — see the Biomarker Testing Guide linked in School 02 above.

What does treatment resistance mean?

Treatment resistance means cancer becomes less responsive or stops responding to a treatment. Mechanisms can include genetic changes, pathway adaptation, altered drug sensitivity, immune escape, and changes in the tumor environment.

What is the metabolic theory of cancer and the five-axis model?

The metabolic theory, championed by Thomas Seyfried and Paul Marik, proposes cancer is fundamentally a metabolic disease driven by mitochondrial dysfunction and the Warburg Effect (aerobic glycolysis). Dr. Marik's five-axis metabolic trap addresses cancer through five simultaneous pressure points: glucose/glycolysis inhibition, glutamine pathway targeting, fatty acid oxidation disruption, immune/TME reprogramming, and cancer stem cell suppression. Ivermectin is described as a "network amplifier" acting across multiple axes simultaneously. This remains an emerging (E1–E2) framework, not an established clinical standard.

What is fenbendazole, and why is it featured here?

Fenbendazole is an animal deworming drug that preclinical studies and anecdotal reports suggest may have anticancer properties via microtubule disruption, glycolysis inhibition (HK2), p53 activation, and autophagy induction. The Joe Tippens Protocol (fenbendazole 222mg, 3 days on / 4 days off, with vitamin E succinate, curcumin, and CBD) popularized its use after Joe Tippens reported remission from metastatic small-cell lung cancer in 2017 and has since reported remaining cancer-free for multiple years. Fenbendazole has no regulatory approval for human cancer treatment. Evidence remains primarily preclinical and anecdotal (E1–E2). Always consult a physician.

Does this resource promote "alternative" cancer treatments?

No. This library does not treat the terms "alternative" or "integrative" as evidence categories. Any intervention is evaluated according to the quality of evidence supporting it, potential benefits, risks, interactions, and its relationship to established cancer care.

What nutraceuticals have the strongest anticancer evidence?

Vitamin D3, curcumin, EGCG (green tea extract), omega-3 fatty acids, berberine, sulforaphane, modified citrus pectin, and molecular hydrogen have the broadest evidence base in this library, each at roughly E2–E3. See the full supplement review for dosing and cancer-type relevance.

What is the ROOTS / I-PREVENT cancer prevention protocol?

ROOTS is Dr. Paul Marik's evidence-informed framework for cancer prevention, addressing root metabolic and lifestyle drivers of cancer initiation, covering diet, physical activity, metabolic health, and targeted supplementation for breast, colorectal, melanoma, and prostate cancers. I-PREVENT is OneDayMD's parallel prevention framework covering diet, lifestyle, and evidence-based supplementation.

Can I use this guide to prepare for an oncology appointment?

Yes. One of this resource's main purposes is to help patients understand terminology and prepare informed questions for their healthcare team, using the Seven Questions framework above as a starting point.

How do I find trusted oncologists or integrative cancer physicians?

Use the Find Oncologists directory linked in Resource Guides above. The Wellness Company (TWC) also provides access to integrative medicine physicians — code ONEDAYMD provides a referral discount (affiliate link; see disclosure above).

Where does this content come from, and how often is it updated?

This page connects patient education with deeper OneDayMD and Cancer Advisor research articles, plus Dr. Paul Marik's Cancer & Metabolic Library. It is a living document updated continuously as new research and articles are published across the network; this merged edition was last updated August 2026.

Can AI tools like Claude or ChatGPT help me use this library?

Yes — see the Using AI to Personalize Your Research section above for suggested prompts for Claude, ChatGPT, Perplexity, and Gemini. AI outputs should be used as conversation starters with your oncologist, not as a substitute for their guidance.

Medical & Safety Disclaimer

Educational use only. This page provides general health and cancer information for educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease and does not constitute medical advice.

Cancer treatment is individualized. Decisions about surgery, radiation, chemotherapy, immunotherapy, targeted therapy, clinical trials, supportive care, supplements, or any other intervention should be made with appropriately qualified healthcare professionals who know the patient's medical history and clinical circumstances.

Experimental, repurposed, complementary, or integrative interventions should not be assumed to be effective simply because laboratory, observational, or early clinical evidence exists. Evidence strength, safety, interactions, contraindications, and regulatory status must be considered separately. Repurposed drugs discussed on this page are not approved by regulatory agencies (FDA, EMA, or equivalent) for the treatment of cancer unless otherwise stated.

If you have symptoms that could represent a medical emergency, seek appropriate emergency medical care rather than relying on information on this website.

Start With the Question That Matters Most to You

You do not need to understand all of oncology at once. Start with your cancer type, your test results, or your current treatment question — then follow the evidence.

Start the Patient Journey Explore the Cancer Library Find a Doctor

Smart Cancer | OneDayMD Editorial Team · Last Updated: August 2026 · About Us · Part of the OneDayMD health information network. This page is a living document updated continuously as new research and articles are published across the network. © 2020–2026 OneDayMD.com. All Rights Reserved.